Sanofi to pay $11.6bn for Bioverativ for haemophilia biz and commercial network
Sanofi has agreed to buy Bioverativ Inc. for $11.6bn for haemophilia business and to help develop its candidate RNAi therapeutic fitusiran.
Archives for January 23, 2018
Celgene buying T-cell tech partner Juno for $9bn
Celgene will add chimeric antigen receptor (CAR) and T-cell receptor (TCR) technologies through the acquisition of its immune-oncology partner Juno Therapeutics.